Please cite anti-TNF ARTICLE IN PRESS+ModelBONSOI-3063; No. of Pages 6 Joint Bone Spine xxx (2009) xxx–xxx

Hooper Et Al. Pediatric Rheumatology

August 2016

Full list of author information is available at the end of the articleBackground The role of tumor n...

Jean-luc Davignon
Delphine Nigon
Arnaud Constantin
Alain Cantagrel
Jean-luc Davignon
Delphine Nigon
Arnaud Con
Alain Cantagrel

January 2012

response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments

Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis -- Data from the Dutch Arthritis and Biologicals in Children Register, 1999-2010

Otten, M.H.
Prince, F.H.
Twilt, M.
Cate, R. ten
Armbrust, W.
Hoppenreijs, E.P.A.H.
Koopman-Keemink, Y.
Wulffraat, N.M.
Gorter, S.L.
Dolman, K.M.
Swart, J.F.
Berg, J.M. van den
Rossum, M.A. van
Suijlekom-Smit, L.W. van

January 2011

Item does not contain fulltextOBJECTIVE: To evaluate the effectiveness and safety of biological agen...

Arthritis

Rheumatology Biologics
Register Rheumatoid
Katie L. Druce
Gareth T. Jones
Gary J. Macfarlane
Neil Basu

September 2016

Original article doi:10.1093/rheumatology/keu390 Patients receiving anti-TNF therapies experienc

RESEARCH ARTICLE Abatacept decreases disea n n

August 2016

immune disease affecting the joints in approximately 1 % of the world’s population [1, 2]. Patients ...

HOW TO CITE THIS ARTICLE

Catharina Eriksson
Stefan Engstr
Karl-gösta Sundqvist
Solbritt Rantapää-dahlqvist

October 2016

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy

Original article

Sophine B. Krintel
Veit Peter Grunert
Merete L. Hetl
Julia S. Johansen
Matthias Rothfuss
Laurent Essioux
Ursula Klause

August 2016

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine...

Editorial

January 2005

The response to anti-TNF-a treatment: gene regulation at the bedside Approximately 40 % of the patie...

Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Sánchez-Cano, Daniel
Callejas-Rubio, José Luis
Ruiz-Villaverde, Ricardo
Ríos-Fernández, Raquel
Ortego-Centeno, Norberto

August 2013

Journal Article; Review;Tumoral necrosis factor α plays a central role in both the inflammatory resp...

Risk of infection in rheumatoid arthritis patients treated with TNF-α antagonists: a systematic review

Barbosa, Ana
Santos, Marlene

November 2015

Rheumatoid arthritis is an autoimmune disease characterized by chronic joint inflammation that leads...

Imágenes clínicas: tofo óseo y subcutáneo

Anaya, Juan-Manuel
Delgado, Jorge

August 2020

The therapeutic effect of tumor necrosis factor (TNF)inhibition is certainly well recognized from st...

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

Hiltunen, J.
Parmanne, P.
Sokka, T.
Lamberg, T.
Isomäki, P.
Kaipiainen-Seppänen, O.
Peltomaa, R.
Uutela, T.
Pirilä, L.
Taimen, K.
Kauppi, M. J.
Yli-Kerttula, T.
Tuompo, R.
Relas, H.
Kortelainen, S.
Paalanen, K.
Asikainen, J.
Ekman, P.
Santisteban, A.
Vidqvist, K. L.
Tadesse, K.
Romu, M.
Borodina, J.
Elfving, P.
Valleala, H.
Leirisalo-Repo, M.
Rantalaiho, V.
Kautiainen, H.
Jokiranta, T. S.
Eklund, K. K.
for the FinADASpA Study Group

January 2022

Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous a...

Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha

Machado, P
Santos, A
Pereira, C
Loureiro, C
Silva, J
Chieira, C
Malcata, AB

January 2009

INTRODUCTION: Tumour necrosis factor alpha (TNFalpha) has emerged as a therapeutic target in chronic...

Original article Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for

Rheumatology Biologics Register
Paul A. C. Lord
Tracey M. Farragher
Mark Lunt
Kath D. Watson
Deborah P. M. Symmons
Kimme L. Hyrich
Bsr Biologics Register

July 2015

Objective. Few data exist on the use of anti-TNF drugs for AS during routine clinical use in the UK....

LETTER

September 2016

TNF antagonists and shingles: is vaccination advisable? We read with interest the report by Galloway...

RESEARCH a r

Hooper Et Al. Pediatric Rheumatology

August 2016

Full list of author information is available at the end of the articleBackground The role of tumor n...

To cite this version:

Jean-luc Davignon
Delphine Nigon
Arnaud Constantin
Alain Cantagrel
Jean-luc Davignon
Delphine Nigon
Arnaud Con
Alain Cantagrel

January 2012

response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments

Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis -- Data from the Dutch Arthritis and Biologicals in Children Register, 1999-2010

Otten, M.H.
Prince, F.H.
Twilt, M.
Cate, R. ten
Armbrust, W.
Hoppenreijs, E.P.A.H.
Koopman-Keemink, Y.
Wulffraat, N.M.
Gorter, S.L.
Dolman, K.M.
Swart, J.F.
Berg, J.M. van den
Rossum, M.A. van
Suijlekom-Smit, L.W. van

January 2011

Item does not contain fulltextOBJECTIVE: To evaluate the effectiveness and safety of biological agen...

Arthritis

Rheumatology Biologics
Register Rheumatoid
Katie L. Druce
Gareth T. Jones
Gary J. Macfarlane
Neil Basu

September 2016

Original article doi:10.1093/rheumatology/keu390 Patients receiving anti-TNF therapies experienc

RESEARCH ARTICLE Abatacept decreases disea n n

August 2016

immune disease affecting the joints in approximately 1 % of the world’s population [1, 2]. Patients ...

HOW TO CITE THIS ARTICLE

Catharina Eriksson
Stefan Engstr
Karl-gösta Sundqvist
Solbritt Rantapää-dahlqvist

October 2016

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy

Original article

Sophine B. Krintel
Veit Peter Grunert
Merete L. Hetl
Julia S. Johansen
Matthias Rothfuss
Laurent Essioux
Ursula Klause

August 2016

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine...

Editorial

January 2005

The response to anti-TNF-a treatment: gene regulation at the bedside Approximately 40 % of the patie...

Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Sánchez-Cano, Daniel
Callejas-Rubio, José Luis
Ruiz-Villaverde, Ricardo
Ríos-Fernández, Raquel
Ortego-Centeno, Norberto

August 2013

Journal Article; Review;Tumoral necrosis factor α plays a central role in both the inflammatory resp...

Risk of infection in rheumatoid arthritis patients treated with TNF-α antagonists: a systematic review

Barbosa, Ana
Santos, Marlene

November 2015

Rheumatoid arthritis is an autoimmune disease characterized by chronic joint inflammation that leads...

Imágenes clínicas: tofo óseo y subcutáneo

Anaya, Juan-Manuel
Delgado, Jorge

August 2020

The therapeutic effect of tumor necrosis factor (TNF)inhibition is certainly well recognized from st...

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

Hiltunen, J.
Parmanne, P.
Sokka, T.
Lamberg, T.
Isomäki, P.
Kaipiainen-Seppänen, O.
Peltomaa, R.
Uutela, T.
Pirilä, L.
Taimen, K.
Kauppi, M. J.
Yli-Kerttula, T.
Tuompo, R.
Relas, H.
Kortelainen, S.
Paalanen, K.
Asikainen, J.
Ekman, P.
Santisteban, A.
Vidqvist, K. L.
Tadesse, K.
Romu, M.
Borodina, J.
Elfving, P.
Valleala, H.
Leirisalo-Repo, M.
Rantalaiho, V.
Kautiainen, H.
Jokiranta, T. S.
Eklund, K. K.
for the FinADASpA Study Group

January 2022

Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous a...

Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha

Machado, P
Santos, A
Pereira, C
Loureiro, C
Silva, J
Chieira, C
Malcata, AB

January 2009

INTRODUCTION: Tumour necrosis factor alpha (TNFalpha) has emerged as a therapeutic target in chronic...

Original article Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for

Rheumatology Biologics Register
Paul A. C. Lord
Tracey M. Farragher
Mark Lunt
Kath D. Watson
Deborah P. M. Symmons
Kimme L. Hyrich
Bsr Biologics Register

July 2015

Objective. Few data exist on the use of anti-TNF drugs for AS during routine clinical use in the UK....

LETTER

September 2016

TNF antagonists and shingles: is vaccination advisable? We read with interest the report by Galloway...

RESEARCH a r

Hooper Et Al. Pediatric Rheumatology

August 2016

Full list of author information is available at the end of the articleBackground The role of tumor n...

To cite this version:

Jean-luc Davignon
Delphine Nigon
Arnaud Constantin
Alain Cantagrel
Jean-luc Davignon
Delphine Nigon
Arnaud Con
Alain Cantagrel

January 2012

response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments

Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis -- Data from the Dutch Arthritis and Biologicals in Children Register, 1999-2010

Otten, M.H.
Prince, F.H.
Twilt, M.
Cate, R. ten
Armbrust, W.
Hoppenreijs, E.P.A.H.
Koopman-Keemink, Y.
Wulffraat, N.M.
Gorter, S.L.
Dolman, K.M.
Swart, J.F.
Berg, J.M. van den
Rossum, M.A. van
Suijlekom-Smit, L.W. van

January 2011

Item does not contain fulltextOBJECTIVE: To evaluate the effectiveness and safety of biological agen...

Please cite anti-TNF ARTICLE IN PRESS+ModelBONSOI-3063; No. of Pages 6 Joint Bone Spine xxx (2009) xxx–xxx

Abstract

Extracted data

Please cite anti-TNF ARTICLE IN PRESS+ModelBONSOI-3063; No. of Pages 6 Joint Bone Spine xxx (2009) xxx–xxx

Abstract

Extracted data

Related items

Related items